Our Clinical Research
Myelofibrosis (MF) - POIESIS
Status: Recruiting
ClinicalTrials.gov: NCT06479135Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Myelofibrosis (MF)
Status: Active, Not Recruiting
ClinicalTrials.gov: NCT04485260An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of Navtemadlin (KRT-232) Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib.
Myelofibrosis (MF) - BOREAS
Status: Active, Not Recruiting
ClinicalTrials.gov: NCT03662126Navtemadlin (KRT-232) Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)
Myelofibrosis (MF)
Status: Active, Not Recruiting
ClinicalTrials.gov: NCT04878003An Open-Label, Multicenter, Phase 2 Study Assessing the Safety and Efficacy of Navtemadlin (KRT-232) in Janus-associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
Expanded Access Program
Expanded access, also known as “compassionate use,” refers to the use of an investigational agent outside of a clinical trial. This is a U.S. Food and Drug Administration (FDA) initiative that allows patients with serious illnesses, who have exhausted all other treatment options, the opportunity to access investigational agents that are not yet approved. It is important to remember that the safety and efficacy of these agents have not yet been established. Physicians and patients should discuss all possible benefits and risks before seeking expanded access to an investigational agent.
Kartos Therapeutics will evaluate each request for expanded access to KRT-232. All requests must be submitted to eap@kartosthera.com by a licensed healthcare professional. We will review the request promptly and respond within 48 hours.
For more information on the FDA Expanded Access program, please see the FDA website on Expanded Access, and/or talk to your healthcare provider.